Jefferies rates Allergy Therapeutics at buy

Allergy Therapeutics plc was rated by Jefferies & Co., Inc. analyst Robin Campbell at a buy following a site visit to the company's Worthing facility. The company has the opportunity to transform the treatment of allergic disorders with its Pollinex Quattro (PQ) ultra short course allergy vaccines. The analyst looks for the company to start U.S./global phase 3 trials. Shares of the Worthing, U.K.-based pharmaceutical company were up 28p, or 0.29%, at 98.28p on volume of 4,084 shares versus the three-month running average of 196,677 shares. (London: AGY)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.